Hungary vs Mus: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Hungary
99.0%
in 2025
Mus
98.0%
in 2025
Hungary rank
1st
Mus rank
1st
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Hungary
- Mus
How they compare
Hungary currently reports 99.0% against 98.0% in Mus, a difference of 1.0%.
The two have swapped places 1 time across 18 shared years of data; in 2008 it was Mus ahead.
Hungary ranks 1st and Mus ranks 1st of 194 countries.
Hungary has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Hungary | Mus | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | — |
| 2010s | 84.8% | 28.7% | 56.1% | Hungary |
| 2020s | 99.0% | 95.0% | 4.0% | Hungary |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Hungary or Mus?
- Hungary, at 99.0% against 98.0% in Mus as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Hungary and Mus?
- 1.0%, with Hungary ahead.
- How many years of comparable data are there for Hungary and Mus?
- 18 years are reported by both, from 2008 to 2025.
- How do Hungary and Mus rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Hungary ranks 1st and Mus ranks 1st of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.